rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    OKYO
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      OKYO Pharma to Participate in 2026 Jefferies Global Healthcare Conference in London
      Nov 12Yahoo FinanceOKYO
      OKYO Pharma to Present at the Stifel 2026 Healthcare Conference

      LONDON and NEW YORK, Nov. 05, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that it will participate at the Stifel 2026 Healthcare Conference November 10–12, 2026. Robert J. Dempsey, Chief Executive Officer, is scheduled to present at 9:20 a.m. ET on Thursday, November 12, 2026, at the Stifel 2026 Hea

      Nov 5Yahoo FinanceOKYO
      Analysts Have Conflicting Sentiments on These Healthcare Companies: Aclaris Therapeutics (ACRS), Globus Medical (GMED) and Johnson & Johnson (JNJ)

      Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.

      Oct 8The Globe and MailACRSOKYOGMEDJNJ
      H.C. Wainwright reiterates Okyo Pharma stock rating on trial enrollment
      Oct 7Investing.comOKYO
      OKYO Pharma Enrolls First Patients in Phase 3 NEPTUNE Trial of Urcosimod for Neuropathic Corneal Pain

      Detailed price information for Okyo Pharma Limited ADR (OKYO-Q) from The Globe and Mail including charting and trades.

      Oct 7The Globe and MailOKYO
      OKYO Pharma enrolls first patients in Phase 3 trial of neuropathic corneal pain drug
      Oct 6Yahoo FinanceOKYO
      OKYO Pharma Announces First Patients Enrolled in Phase 3 Pivotal Trial of Urcosimod for Neuropathic Corneal Pain
      Oct 6Yahoo FinanceOKYO
      OKYO Pharma Presents and Participates at Upcoming Ophthalmic Scientific Conferences
      Sep 29Yahoo FinanceOKYO
      OKYO Pharma to Present at Ophthalmology Futures European Forum and iNovation Day at ESCRS 2026

      Company to engage with the global ophthalmology and investment community as it advances urcosimod through its global Phase 3 pivotal trial for neuropathic corneal painLONDON and NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that it will present at Ophthalmology Futures Forum and in

      Sep 9Yahoo FinanceOKYO
      OKYO Pharma to Highlight Urcosimod Progress at Cantor Global Healthcare Conference

      Detailed price information for Okyo Pharma Limited ADR (OKYO-Q) from The Globe and Mail including charting and trades.

      Sep 9The Globe and MailOKYO
      OKYO Pharma to Participate in a Fireside Chat at the Cantor Global Healthcare Conference
      Sep 8Yahoo FinanceOKYO

      This is the newest page. Registered accounts read further back.